ASML.US may enter the hybrid bonding market to challenge BE Semiconductor Industries (BESIY.US) leading position. Bank of America downgraded BESIY.US to “Neutral” and nearly halved its target price.
Bank of America believes that the current share price of the Dutch semiconductor equipment manufacturer BE Semiconductor Industries does not yet fully reflect the potential competitive threat from ASML.
According to Golden Ten Data APP, Bank of America believes that the current stock price of Dutch semiconductor equipment manufacturer BE Semiconductor Industries (BESIY.US) has not yet fully reflected the potential competitive threat from ASML (ASML.US). The bank downgraded BE Semiconductor Industries’ rating from "Buy" to "Neutral" and lowered its target price by nearly half. As a result, the stock fell by more than 6% on Tuesday.
BE Semiconductor Industries currently holds a leading position in the Hybrid Bonding equipment market. Hybrid Bonding is an emerging advanced packaging technology that enables direct connection between two chip surfaces, eliminating traditional metal bumps and thereby improving chip interconnect density and heat dissipation efficiency. With rising demand for advanced packaging technologies driven by AI chips and high bandwidth memory products, this technology has become a key pillar for the company’s future growth prospects.
Bernstein analysts estimate that by 2028, about three-quarters of hybrid bonding equipment shipped worldwide may come from BE Semiconductor Industries. The company itself holds high expectations for this market. In an optimistic scenario, it expects the number of hybrid bonding devices shipped to exceed 2,000 units by 2030, while by the end of 2025, its cumulative order volume will only surpass 150 units.
However, Bank of America analysts led by Didier Scemama point out that BE Semiconductor Industries’ leading position faces new uncertainties, the most noteworthy of which is that ASML has publicly expressed its intention to enter the hybrid bonding market.
Bank of America states that companies like ASML may enter BE Semiconductor Industries’ most important growth market. Combined with the possibility that BE Semiconductor Industries may have to increase R&D spending in the future, these risks have not yet been fully reflected in the stock price. Before ASML’s specific plans become more clear, this factor may continue to weigh on BE Semiconductor Industries’ valuation. Nevertheless, Bank of America has not currently assumed that ASML will ultimately capture a large market share.
Last year, ASML delivered its first advanced packaging product. In April this year, ASML CEO Christophe Fouquet stated during an earnings call that the company would continue to explore ways to support customers using hybrid bonding technology.
Bank of America believes that ASML’s potential advantage relates to the technical bottlenecks currently facing hybrid bonding. One major issue hindering the large-scale adoption of this technology is low production yields; manufacturers still find it difficult to produce a sufficient and stable quantity of qualified chips. As multiple logic or memory chips are stacked, precision requirements for the equipment also rise. ASML’s accumulated technical capabilities in high-precision, high-speed lithography could create opportunities for its entry into this market.
BE Semiconductor Industries’ stock price has been under significant pressure recently. As investors worry that memory chip makers may delay adopting hybrid bonding technology and other factors, the stock has fallen by about one-third cumulatively in the third quarter, making it the worst-performing component in the STOXX 600 Index over the same period. Still, even after a sharp correction, BE Semiconductor Industries has gained around 45% so far this year.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
Humana shares soar as it becomes the biggest beneficiary of the 2027 Medicare star ratings.
Reuters, October 9 – In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose by 15%. Analysts said the health insurer is set to be the biggest beneficiary of the new 2027 Medicare Advantage star ratings. Humana stated that, with improvements in healthcare quality and member experience indicators, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher by 2027, a substantial jump from 20% in 2026 (link). JPMorgan analysts noted that they had previously projected this ratio to be between 60% and 70%. The U.S. Department of Health and Human Services uses a one- to five-star scale to rate Medicare Advantage and prescription drug plans. Higher ratings lead to government bonuses worth billions of dollars and can help attract more members. Analysts noted that Humana’s ratings performance outpaced its larger competitors: JPMorgan expects the proportion of UnitedHealth Group’s (UNH.N) plans rated four stars or higher to decrease from 81% to about 67%, while CVS Health’s (CVS.N) ratio will fall from 84% to about 70%. The U.S. Department of Health and Human Services said Thursday night that, overall, about 71% (link) of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027. Evercore ISI analyst Elizabeth Anderson said that Humana had improved in prescription drug plan quality, health plan quality, and readmission rates. She added, “This improvement reflects management’s increased focus on these metrics over the past year.” Health insurers provide Medicare Advantage plans for the government to adults aged 65 and older and people with disabilities.
Illia Polosukhin: NEAR accounts can achieve quantum resistance through key updates
Crypto prices
More
